Treg cells for graft-versus-host disease after transplant
Part of Immune system & allergy clinical trials.
This study tests whether special cells from your donor, called Treg cells (a type of immune cell that calms inflammation), can help treat graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have already tried other treatments but still have GVHD symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have had a stem cell transplant from a donor.
- You currently have graft-versus-host disease (GVHD) that needs treatment with medication.
- You have tried between 1 and 5 previous treatments for GVHD (including steroids).
- Your steroid dose has been stable for the last 2 weeks, or you have been on a moderate-to-high dose for 4 weeks without improvement, or you've tried to lower the dose twice and couldn't.
- You are able to take care of yourself (ECOG score 0 or 1) and your doctor expects you to live longer than 12 months.
- Your blood counts (neutrophils and platelets) and organ function (liver, kidney) are within certain limits, and you do not have uncontrolled heart disease or other serious conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests two different medicines (ATG-thymoglobulin and ATLG-grafalon) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for older adults with certain blood cancers who have a matched unrelated donor.
This trial tests whether injecting special immune cells (Treg cells) from your transplant donor, along with a protein called IL-2, can help control chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. It is for people who have had a stem cell transplant and still have moderate to severe cGVHD.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This trial tests whether a special type of immune cell (called CD8 regulatory precursors) can help prevent the body from rejecting a stem cell transplant from a donor. It is for patients receiving a stem cell transplant from a related donor.
This trial tests if a two-step course of a drug called ATG (anti-thymocyte globulin) can help prevent a serious side effect called graft-versus-host disease (GVHD) after a donor stem cell transplant. It is for people with certain blood cancers who are receiving a reduced-intensity transplant.
Hear when a new GVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.